All news

Ruiyi Xulian raises about ¥100 million for brain-spine interface

Prepared by Sintelligent with the help of SI. Published in SI: . Updated: .

The funds raised will go toward BSI clinical trials and the organization of serial production of the implantable "read-write" platform.

Suzhou-based Suzhou Ruiyi Xulian Medical Technology has closed a Pre-A+ round of nearly ¥100 million, financial adviser Xingqiao Capital reported on November 19. Puhua Capital and Furon Investment led the round, with Songhe Capital and Beijing Industrial Investment also participating. The proceeds will go toward moving the key product — the brain-spine interface (BSI) — into clinical trials. They will also fund the launch of serial production of a modular implantable bidirectional "read-write" platform. Another goal is expanding indications: speech decoding, vision restoration and depression.